Back

Innovent expands Phase 3 IBI363 trial to non-squamous lung cancer patients

Verifying
  • Innovent expanded MarsLight-11 to evaluate IBI363 in non-squamous NSCLC patients.
  • MarsLight-11 compares IBI363 monotherapy with docetaxel in two independent Phase 3 substudies.
  • Innovent and Takeda signed their global license and collaboration agreement in October 2025.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.